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Research Needs for Hepatic
Injury Due to Environmental Agents
by Philip S. Guzelian*
This report presents an overview of the patterns of liver injury produced by presently
recognized toxic substances in the environment. Current concepts ofthe metabolic disposition of
these substances in the liver suggest that their toxic effects may be modulated by an interplay
between enzymatic pathways for activation or inactivation of foreign compounds. A better
understanding of the genetic control of the enzymes involved in these pathways, as well as the
mechanisms ofcell death or malignancy produced by the products ofthese pathways, is needed.
Although a number of sensitive biochemical tests of liver function are currently available,
development ofspecific, noninvasive screening tests forthe earliest manifestations ofliver injury
are urgently needed.
The liver plays a central role in mediating the
interaction between man and his chemical environ-
ment. The liver is not only a target organ for toxic
effects ofmany environmental substances, but also
the major site for biotransformation of foreign
chemicals that enterthe body. A list ofthe patterns
of liver toxicity produced by noninfectious condi-
tions other than therapeutic agents is presented in
Table 1 (1-3). Some industrial chemicals or contam-
inants naturally found in food products regularly
produced dose-dependent hepatic necrosis. Chole-
stasis, when appearing as the sole manifestation of
liver injury, is rare (4). Liver injury due to envi-
ronmental agents is often nonspecific and incon-
spicuous. This presents a challenge to the clinician
or epidemiologist in establishing a cause-and-effect
relationship between a contact with an environ-
mental agent and liver toxicity. Examples include
fatty metamorphosis detected only by liver biopsy,
orhypertrophy ofthe endoplasmic reticulum (micro-
some induction). In the United States, veno-
occlusivedisease, granulomas, orhepatoportalfibrosis
have been associated only with a limited number of
toxic substances. Cirrhosis has been found in indus-
trial workers exposed to chlorinated organic com-
pounds or to plant toxins, but this, too, has been
observed only infrequently.
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Hepatoma, the most common form of malignan-
cy, worldwide, isassociatedwithgeographicregions
in which both hepatitis B virus and aflatoxin are
endemic (5). In the Western world, ethanol con-
sumption is most commonly associated with hepa-
tocellularcarcinoma, althoughitisuncertainwhether
ethanol is a carcinogen per se, or whether ethanol
evokes malignancy by producing cirrhosis, a fre-
quent precursor of hepatoma. An important unre-
solved question is whether some or all ofthe many
halogenated aliphatic, aromatic, or polycyclic com-
poundsthat causehepatocellularcarcinomainexper-
imental animals also are carcinogens for human
liver. Angiosarcoma, a rare tumor arising from the
epithelial cells of the liver sinusoid (6), was a rare
tumor prior to its emergence in vinyl chloride
workers (7) or in people exposed to arsenic or
Thorotrast (7).
Research Needs in the
Pathophysiology of Hepatocellular
Toxicity
A simplified schematic representation of the
pathwaysforbiotransfornation offoreign substances
in the liver is presented in Figure 1. Most often,
environmental agents are lipophilic and, hence, are
notreadily excreted in aqueous media such as urine
or bile. Hepatic metabolism converts these sub-
stances to more polar, readily excretable forms.P. S. GUZELIAN
Table 1. Summary of syndromes of hepatotoxicity due to environmental agents.
Toxic manifestation Examples of environmental toxins reported in man
Acute or subacute hepatic necrosis Chlorinated aliphatics in high doses (CC14, tetrachloroethane); mushroom toxins;
phosphorus; mycotoxins; high doses of polychlorinated biphenyls (PCB's)
Cholestasis Methylene diamine (Epping jaundice); dinitrophenol; chromium
Mild fatty metamorphosis Small doses of chlorinated aliphatics; some organochlorine pesticides
Hypertrophy of endoplasmic reticulum Polychlorinated biphenyls; some organochlorine pesticides
Veno-occlusive disease Plant toxins (pyrrolidizine alkaloids); therapeutic liver irradiation
Granuloma Beryllium
Hepatoportal fibrosis Vinyl chloride; arsenic
Cirrhosis Chlorinated aliphatics; aromatics; aflatoxin; arsenic; plant toxins
Hepatocellular carcinoma Aflatoxin; ? ethanol
Angiosarcoma Vinyl chloride; arsenic
This involves reactions carried out largely in the
endoplasmic reticulum ofthe hepatocyte, catalyzed
by cytochrome P-450. This group of hemoprotein
isoenzymes oxidizes many foreign substances (8,9).
In some instances, bio-oxidation of foreign com-
pounds renders them pharmacologically inactive,
although most potentially toxic compounds require
similar bio-oxidation reactions to be converted into
toxic forms (metabolic activation). Unless promptly
disposed of, these oxygenated metabolites may
interact chemically with nucleic acids or other
mamromolecules in the hepatocyte, initiating a
chain of events ultimately thought to lead to
malignancy or cytotoxicity. Prompt removal of
metabolically activated toxic substances is carried
out by a series of conjugating enzymes capable of
converting these metabolites to water-soluble deriv-
atives that are inactive pharmacologically (detoxi-
fication). It may be reasoned that the metabolic
disposition of a foreign compound in the liver will
depend upon not only the dose, but also upon
differences between the rates of enzymatic activa-
tion ofthe compound, counteracted bythe availabil-
ity of pathways of inactivation of its reactive
metabolites. Hence, factors that alter the levels of
activating or detoxifying enzymes in the liver may
be important determinants of the presence or
absence of toxicity. It is well recognized that
cytochrome P-450 is inducible by many environ-
mental compounds including lipophilic drugs, some
natural agents, carcinogens and environmental
pollutants (9,10). For example, following admini-
stration to experimental animals of many organo-
chlorine pesticides or polycyclic aromatic hydro-
carbons, there is a rise in the concentration of
hepatic cytochrome P-450. This appears to be an
adaptive response ofthe liver since the cytochrome
concentration promptly falls once the amounts of
these chemicals in the liver have been sufficiently
reduced through metabolism or redistribution to
other tissues to remove the stimulus to cytochrome
induction. There is substantial evidence in animals
and growing evidence in man that the amounts of
cytochrome P-450 and its inducibility are under
genetic control (11). The level ofcytochrome P-450
may be decreased in many physiologic or patho-
physiologic states (12).
Remarkable progress has been made over the
last 15 years in isolating and characterizing these
hemoproteins and inunderstandingtheirregulation
in the liver. As with the cytochrome P-450 system,
there is intense interest in elucidating these conju-
gating enzymes which include cytoplasmic gluta-
thione-S-transferases, and microsomal glucuronyl
transferases and epoxide hydratases. Future sup-
port should be given to efforts to characterize the
structure and regulation of cytochrome(s) P-450
and other classes of enzymes catalyzing biotrans-
formation of environmental agents. The recent
availability of advanced techniques in recombinant
DNA and molecular genetics should facilitate prog-
ress in phenotyping individuals in an effort to
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FIGURE 1. Generalized pathways for hepatic disposition of
environmental chemicals. Reproduced by permission (49).
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understand interindividual variations in sensitivity
to toxic substances (13,14). An extremely impor-
tant category of compounds commonly found in
toxic dump sites are those extremely hydrophobic
chemicals (e.g., organochlorine pesticides) that
undergo little (if any) metabolism and elimination
by the liver (Fig. 1). Chronic exposure to small
amounts ofthese chemicals leads to their accumula-
tion in tissues and membrane lipids. We know little
regarding the biochemical and biophysical aspects
of this sequestration and of the basic forces that
establish distribution of these chemicals in the
body. Further, since many ofthese compounds are
toxic or carcinogenic to rodent liver, there is
concern that these chemicals may also foster malig-
nancies in human tissue. For this reason, efforts
should be made to understand the mechanism of
their carcinogenesis in animals. For example, do
they act as "promotors" of biochemically initiated
premalignant hepatocytes (see below), or do they
provide a stimulus to induction ofcytochrome P-450
and, hence, render the individual more susceptible
to other procarcinogens?
Research Needs in the
Pathophysiology of
Hepatocellular Carcinoma
The problems ofextrapolation from experimental
animals to humans are perhaps nowhere better
illustrated than in the subject of hepatocellular
carcinoma. Despite the fact that many persistent
chemicals in the environment cause liver tumors
when administered at high doses to experimental
animals, it is as yet unknown whether or not
organochlorine pesticides, polyhalogenated biphe-
nyls, etc., also produce cancer in humans exposed
chronically to small amounts of these substances.
Investigation of this problem in humans is difficult
because the latent period for emergence of human
malignancy is long, and because epidemiology is a
relatively insensitive tool for establishing causation
in human carcinogenesis unless the tumor is rare or
unless the carcinogen is extremely potent. Solving
this problem will undoubtedly require a combined
approach usingimproved methods forclinical inves-
tigation ofchemical carcinogenesis (see below, liver
function tests) and also better experimental models
that permit elucidation of the mechanisms of carci-
nogenesis ofthese chemicals andtheirdose-response
relationships.
An exciting new advance in the pathophysiology
of experimental chemical carcinogenesis has been
the establishment of a multistage model of liver
cancer, analogous to that previously established for
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FIGURE 2. Farber's multistep model ofexperimental chemical
carcinogenesis in the liver (15). Reproduced by permission
(49).
the skin (15-17). For example, Farber and his
associates have developed a multistep model for
liver carcinogenesis which can, in general, be
divided into two stages (Fig. 2). The first stage,
initiation, can be produced by exposing rats to
known chemical procarcinogens that, when meta-
bolically activated, are capable of interacting with
DNA and producing mutations. These short-term
biochemical changes, however, will resolve imme-
diately unless there is prompt application of a
second stimulus capable of evoking hepatocyte
replication (e.g., partial hepatectomy). Thus, the
initiation process results in conversion of some
normalhepatocytesinto"preneoplastic" hepatocytes.
These postulated cells are irrevocably committed to
retainthe potentialfordevelopingintohepatocellular
carcinomas, and yet they will remain dormant for
the life of the animal unless a second series of
manipulationstermedpromotionisapplied. Although
there are several "promotion" protocols, they all
have in common simultaneous exposure ofthe liver
to a stimulus for hepatocyte replication, combined
with an antimitogenic stimulus. Farber (15) has
proposed that such opposing forces for replication
offer a selective advantage for the preneoplastic
hepatocytes. These cells proliferate, formingfoci or
nodules ofenzyme-altered hyperplastic cells. These
hyperplastic foci will revert to latent preneoplastic
67hepatocytes if the promoting stimuli are stopped.
However, if selection pressures are maintained,
overt hepatocellular carcinomas will develop. It
may be inferred from these models that carcino-
genesis involves sequential exposure to anumberof
stimuli producing a series of rare events that
infrequently lead to cancer. The individual must be
exposed to both initiating and promoting influences
in sufficient amounts and in the correct sequence in
order for cancers to be produced. It is obvious that
models such as these should be most useful for
future attempts to investigate the mechanisms of
carcinogenesis and also forquantitatively establish-
ingdosedependency as a meansforrationaldefinitions
ofpermissible amounts ofinitiators or promotors in
the environment.
Research Needs for Screening
Tests of Liver Function
Attempts to establish cause-and-effect relation-
ships between environmental agents and their
possibletoxiceffectswouldbemeasureablyadvanced
by the availability of suitable screening tests. The
ideal test would be noninvasive, yet sensitive
enough to detect even minor forms of liver injury.
It would be specific for the liver, and would be
economically suitable for use infield testingoflarge
populations ofpeople potentially in contact with the
environmental agent in question. Table 2 lists a
series ofbiochemical tests ofhepatic functions that
are currently available and that could be used for
screening purposes (18). The serum transaminases,
among the most sensitive tests available, reflect
damage to the hepatocyte. The alanine aminotrans-
feraseis specificfortheliver, whereasthe aspartate
aminotransferase may also be affected by cardiac or
skeletalmusclediseases. Alkalinephosphataseactiv-
ity in the serum reflects functional or mechanical
obstruction to bile flow including that produced by
such infiltrative diseases of the liver as tumor
metastases or granulomas. Unfortunately, the test
is not specific for the liver since alkaline phospha-
tase activity is also released into the serum from
bone, placenta and the intestine. Specificity for
liver can be established by isolating alkaline phos-
phatase isoenzymes, or by measuring 5'-nucleoti-
daseactivity. The serumbilirubinalsoreflectsbiliary
obstruction, but this test is less sensitive and may
be affected by changes in hemoglobin metabolism
irrespective ofliverinjury. y-Glutamyltranspeptidase
(GGTP) was initially proposed as a confirmatory
test to establish a hepatobiliary source for elevated
alkaline phosphatase activity. However, unlike alka-
line phosphatase, GGTP is located not only in the
plasma membrane of the hepatocyte, but also
appears in bile ductular cells, and in the endoplas-
mic reticulum ofthe liver parenchymal cell. GGTP
activity is also found in almost every other tissue of
the body with the exception ofbone. Hence, GGTP
maybe elevated by hepatocyte necrosis, by admini-
stration of drugs that produce hypertrophy of the
endoplasmic reticulum of the hepatocyte (micro-
some induction), and by a variety of nonhepatic
conditions. GGTP is frequently elevated by regular
consumption of alcoholic beverages. A new com-
mercially available test of liver function is mea-
surement offasting orpostprandial serumbile acids
(19-23). The liver is solely responsible for the
synthesis and enterohepatic recirculation of bile
acids. Therefore, biliary obstruction, hepatocellular
necrosis, loss in functioning mass ofthe liver due to
fibrosis, or extrahepatic shunts will decrease the
Table 2. Screening tests of liver function.
Test Abnormality Sensitive Liver-specific
Aspartate aminotransferase AST (SGOT) Hepatocyte necrosis Yes No
Alanine aminotransferase ALT (SGPT) Hepatocyte necrosis Yes Yes
Alkaline phosphatase Biliary obstruction Yes No
Infiltrative diseases
Bilirubin Biliary obstruction No No
-y-Glutamyl transpeptidase (GGTP) Biliary obstruction Yes No
Hepatocellular necrosis
Ethanol
Microsome induction
Serum bile acids Biliary obstruction Yes Yes
Hepatocellular necrosis
Extrahepatic shunts
Aminopyrene breath test Microsome induction No No
Functional liver mass
Urinary glucaric acid Microsome induction No No
Urinary 6,-hydroxycortisol Microsome induction No No
a-Fetoprotein Hepatoma Yes No
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capacity of the liver to extract bile acids from the
plasma. The test appears to be as sensitive as the
transaminase enzymes, and except for unusual
circumstances largely reflects liver diseases.
Over the last several years, a series of breath
tests of liver function exemplified by the [14C]-
aminopyrene breath test has been developed (24).
The administered parent drug is labeled with a
radioactive or stable isotope and the labeled metab-
olite, CO2, is collected with a breath-trapping
device. The test appears to be somewhat less
sensitive than the transaminases due to wide over-
lap in the range ofnormal values, but nevertheless
is useful for reflecting microsome hypertrophy of
the endoplasmic reticulum (microsome induction).
These tests may reflect the amount of functioning
liver mass and, therefore, are particularly useful
for repeatedly examining changes in liver function
over time in agiven individual (25). Induction ofthe
endoplasmic reticulum of the liver has also been
monitored by the urinary excretion ofglucaric acid,
a breakdown product ofmicrosomal glucuronic acid
(26-29), orbyurinaryexcretion of6,B-hydroxycortisol
(30), a product of endogenous steroid oxidation in
the liver. Many environmental agents evoke hyper-
trophy of the endoplasmic reticulum as their sole
hepatic manifestation. It should be emphasized that
it is unknown as yet whether this should be termed
a toxic or an adaptive response of the liver. From
the preceding discussion, it may be seen that
induction of hepatic microsomal enzymes could
have either a favorable or an unfavorable effect
(31). Although tests for hepatic microsomal enzyme
induction have been restricted largely to clinical
pharmacologic studies of drugs, they may have
wider application for problems of environmental
chemicals. Therefore, it would be desirable to
develop even more sensitive and specific tests for
this purpose.
a-Fetoprotein is a serum test for the presence of
hepatoma (32). Recently, the sensitivity ofthe test
has been greatly improved by the development ofa
radioimmunoassay (33,34). This test provides the
earliest practical marker ofhepatoma and is useful
for following the development ofthe tumor. Minor
elevations of a-fetoprotein occur with metastatic
tumors to the liver and also in nonneoplastic liver
disease (35).
A potential problem with screening large popula-
tions with liver tests is that abnormalities may be
produced by factors other than exposure to the
toxic substance under investigation. Prominent
among these in Western societies is ethanol. Regu-
lar consumption even ofmodest amounts ofethanol
can produce abnormalities in one or more of the
testslistedinTable2. Histories oftheamountofeth-
anolconsumedarenotoriouslyunreliable. Screening
tests thathavebeenused forestimatingthe presence
andamountofethanolconsumptionincludeAST/ALT
ratio and -y-glutamyl transpeptidase (GGTP). A
simple and efficient test that could be incorporated
in large-scale screening protocols is estimation of
the ratio of the AST to ALT. Characteristically,
ethanol consumption preferentially increases the
AST, whiletheALTremains normalorsignificantly
less elevated (36-41). A second test that has been
reported to be elevated in 60-90% of populations
regularlyconsumingethanolistheserumGGTP(42).
Morespecializedtestscurrentlyunderinvestigation
includethepresenceofanabnormalamountofserum
*transferin (43), plasma urate concentration (44),
and the presence of macrocytosis (44).
We presently lack biochemical or morphologic
markers ofthe carcinogenic process duringthe long
latent period between contact with a carcinogen
and the emergence of hepatocellular cancers. To
help identify patients at risk, we need means to
assess the body burden of the toxins, particularly
their metabolically activated forms. Substantial
improvements over the last ten years in analytic
techniques formeasuringmost environmental chem-
icals have opened the possibility of assaying the
concentrations of these substances even in the
small amounts of material available from needle
biopsies of the liver or tissue fat. However, these
biopsies cannot be readily obtained in large popula-
tion studies and must, by necessity, be restricted to
carefully selected patient populations. Improved
techniques for measuring these substances in blood
are needed. Noninvasive tests such as neutron
irradiation to detect cadmium in human liver in
vivo (45) or nuclear magnetic resonance tomogra-
phy(46) maybeuseful. A secondimportantadvance
in assessing the body burden of potential carcino-
genic materialwould be the opportunity to measure
the amount of stable adducts formed between the
activated carcinogen and genetic material. Two
exciting advances in this area have recently been
reported. Poirier and colleagues (47) have devel-
oped a radioimmunoassay capable of specifically
detecting extremely small amounts of benzo(a)-
pyrene-deoxyguanosine adducts. Bennett and col-
leagues (48) have developed an assay for measuring
the urinary excretion ofaflatoxin-guanine adducts.
Moreover, the latter workers showed that the vast
majorityoftheurinaryadductsofaflatoxin-guanine
adducts were derived from the liver. This impor-
tant advance may provide the first liver-specific
assay ofchemical carcinogenesis. The availabilityof
these and similar assays for chemical carcinogene-
sis in humans would offer promise of a new,
exciting approach for establishing dose-response
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relationships between body burdens of metaboli-
cally activated carcinogens and the subsequent
emergence of toxic or carcinogenic effects.
Summary and Conclusions
Environmental agents are capable of producing
many ofthe same patterns ofliver injury observed
in diseases of the liver caused by virus infection,
drugs, or metabolic or genetic defects. In many
instances, the changes produced are inconspicuous.
Thelong-term consequences, especially withrespect
to contact with animal carcinogens, are unknown.
Substantial progress has been made in identifying
the hepatic enzymes involved in the metabolic
activation and detoxification of environmental sub-
stances. However, additional emphasis should be
placed on elucidating the mechanisms of carcino-
genesis or cell death caused by metabolically acti-
vated substances. Finally, additionalemphasisshould
be placed onthe use ofsensitive and specific tests of
liver function now available or in the process of
development to carry out systematic clinical inves-
tigations of the long-term hepatic effects of envi-
ronmental chemicals.
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